Sai Life Sciences announced the groundbreaking of a new CMC Process R&D Center at its Hyderabad campus. Expected to be operational by September 2026, the facility will double the company’s Process R&D capacity. This expansion will introduce new capabilities in peptide development, oligo intermediates & linkers, formulation development, and early-phase clinical supplies. The investment aims to meet the increasing demand for late-stage development programs.
R&D Center Groundbreaking
Sai Life Sciences has commenced construction of a new CMC Process R&D Center at its integrated R&D campus in Hyderabad. The new facility is scheduled for completion by September 2026, significantly boosting the company’s research and development capabilities.
Expanded Capabilities
The new R&D Center will double the company’s existing Process R&D capacity and add new capabilities, including:
- Peptide development
- Oligo intermediates & linkers
- Formulation development
- Early-phase clinical supplies
These expansions are designed to enhance the company’s ability to support late-stage development programs and scale CMC capacity.
Investment and Capacity
This investment is part of Sai Life Sciences’ planned capital expenditure, driven by increasing demand for late-stage development programs and scalable CMC capacity. The expansion aims to address growing needs for larger clinical-scale programs and a robust late-stage development pipeline.
Facility Details
The upcoming Process R&D Block will feature:
- Total built-up area of 100,000 sq. ft. (9300 sq. m.) over five floors
- 140 process chemistry fume hoods with an integrated satellite analytical lab
- Dedicated laboratories for peptides and oligo intermediates & linkers
- 25,000 sq. ft. centralized analytical laboratory
- NCE formulation development and early-phase clinical supply capabilities
- Kilo lab for early clinical manufacturing
- Containment down to OEL 4 (1 μg/m³)
- Designed as a ‘Green Building’
Source: BSE